Logo for Kura Oncology Inc

Kura Oncology Investor Relations Material

Latest events

Logo for Kura Oncology Inc

Study Update

Kura Oncology
Logo for Kura Oncology

Study Update

9 Dec, 2024
Logo for Kura Oncology

Collaboration

20 Nov, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies

Latest reports from Kura Oncology Inc

Access all reports
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company that develops medicines for the treatment of cancer in the United States. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications.